Payments to Acquire Property, Plant, and Equipment of CRISPR Therapeutics AG from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Summary
CRISPR Therapeutics AG annual and quarterly Payments to Acquire Property, Plant, and Equipment in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • CRISPR Therapeutics AG Payments to Acquire Property, Plant, and Equipment for the quarter ending 31 Mar 2025 was $206,000, a 71% decline year-over-year.
  • CRISPR Therapeutics AG annual Payments to Acquire Property, Plant, and Equipment for 2025 was $914,000, a 52% decline from 2024.
  • CRISPR Therapeutics AG annual Payments to Acquire Property, Plant, and Equipment for 2024 was $1,901,000, a 80% decline from 2023.
  • CRISPR Therapeutics AG annual Payments to Acquire Property, Plant, and Equipment for 2023 was $9,470,000, a 75% decline from 2022.
Source SEC data
View on sec.gov
Payments to Acquire Property, Plant, and Equipment, Annual (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Annual Change (%)
Payments to Acquire Property, Plant, and Equipment, Quarterly (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Quarterly Change (%)

CRISPR Therapeutics AG Annual Payments to Acquire Property, Plant, and Equipment (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $914,000 -$987,000 -52% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $1,901,000 -$7,569,000 -80% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $9,470,000 -$27,718,000 -75% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $37,188,000 -$44,517,000 -54% 01 Jan 2022 31 Dec 2022 10-K 11 Feb 2025 2024 FY
2021 $81,705,000 +$63,347,000 +345% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $18,358,000 +$11,674,000 +175% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $6,684,000 +$3,911,000 +141% 01 Jan 2019 31 Dec 2019 10-K 15 Feb 2022 2021 FY
2018 $2,773,000 -$5,041,000 -65% 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
2017 $7,814,000 +$4,798,000 +159% 01 Jan 2017 31 Dec 2017 10-K 12 Feb 2020 2019 FY
2016 $3,016,000 +$1,862,000 +161% 01 Jan 2016 31 Dec 2016 10-K 25 Feb 2019 2018 FY
2015 $1,154,000 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2018 2017 FY

CRISPR Therapeutics AG Quarterly Payments to Acquire Property, Plant, and Equipment (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $206,000 -$515,000 -71% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q1 2024 $721,000 -$2,338,000 -76% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q1 2023 $3,059,000 -$12,291,000 -80% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $15,350,000 +$8,326,000 +119% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q1 2021 $7,024,000 +$4,033,000 +135% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $2,991,000 +$1,894,000 +173% 01 Jan 2020 31 Mar 2020 10-Q 27 Apr 2021 2021 Q1
Q1 2019 $1,097,000 +$542,000 +98% 01 Jan 2019 31 Mar 2019 10-Q 28 Apr 2020 2020 Q1
Q1 2018 $555,000 -$2,730,000 -83% 01 Jan 2018 31 Mar 2018 10-Q 29 Apr 2019 2019 Q1
Q1 2017 $3,285,000 +$3,053,000 +1316% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q1 2016 $232,000 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.